Clinical Trial Update: A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting completion of a Phase 1/2 study evaluating NT219 alone and in combination with cetuximab (ERBITUX) in adults with advanced solid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• NT219

Snippet

Sponsor: TyrNovo Ltd. | Conditions: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck | Phase 1, Phase 2 | Status: COMPLETED